Physician profile
Chantale O Branson
NPI 1538428826
$17,212.43
in general payments reported to CMS, 2019-2025
29 companies · $13K in 2025
The $13K reported for 2025 was more than what 93% of Sleep Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $337).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.66 · 2020: $67.28 · 2021: $112 · 2022: $766 · 2023: $2,289 · 2024: $1,080 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $4,714 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500 · Education: $25.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,000.00 |
| Food and Beverage | $4,713.93 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
| Education | $25.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $9,400.00 | 2025 | |
| Abbvie INC. | $2,267.98 | 2022-2025 | Botox, Duopa, Ubrelvy |
| Neurocrine Biosciences, INC. | $1,335.74 | 2021-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $914.02 | 2022-2025 | Nuplazid |
| Mdd US Operations, LLC | $575.40 | 2023-2025 | Apokyn, Gocovri, Qelbree |
| Teva Pharmaceuticals USA, INC. | $528.32 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Emd Serono, INC. | $284.32 | 2024 | |
| Medtronic, INC. | $232.90 | 2022-2025 | Percept Pc Brainsense |
| Alexion Pharmaceuticals, INC. | $212.12 | 2023-2024 | Soliris, Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $163.65 | 2025 | Wainua |
| Boston Scientific Corporation | $150.19 | 2023 | |
| Biogen, INC. | $118.70 | 2022-2025 | Skyclarys |
| Kyowa Kirin, INC. | $101.87 | 2022 | |
| Merz Pharmaceuticals, LLC | $101.48 | 2023-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $93.72 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $90.89 | 2024-2025 | Crexont, Rytary |
| Abbott Laboratories | $84.48 | 2020-2025 | Infinity |
| Supernus Pharmaceuticals, INC. | $83.36 | 2025 | |
| F. Hoffmann-La Roche Ag | $80.00 | 2025 | |
| Lilly USA, LLC | $70.22 | 2022-2025 | Zepbound, Kisunla, Mounjaro |
| Argenx US, INC. | $59.41 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Allergan, INC. | $49.97 | 2019-2022 | |
| Celgene Corporation | $48.43 | 2022 | |
| Janssen Biotech, INC. | $40.00 | 2025 | |
| Avion Pharmaceuticals | $28.93 | 2022-2023 | Dhivy |
| Viiv Healthcare Company | $25.08 | 2025 | Apretude |
| Harmony Biosciences LLC | $24.79 | 2023 | Wakix |
| Sage Therapeutics, LLC | $24.60 | 2023 | |
| Acorda Therapeutics, INC | $21.86 | 2023 | Inbrija |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chantale Branson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.